Aim. To analyze the domestic pharmaceutical market of hormonal drugs for assisted reproductive technologies in accordance with the treatment protocols and with the comparison with the State Formulary of Medicines of Ukraine and the British National Formulary. Materials and methods . The study was conducted on the basis of data from the clinical protocols on Assisted Reproductive Technologies (ART), the State Register of Medicinal Products of Ukraine, electronic databases, the Weekly Pharmacy on June 30, 2018, the State Formulary of Ukraine and the British National Formulary. The system, marketing, analytical and comparative analysis methods were used in the research. Results. The system legal support of assisted reproductive technologies in Ukraine has been estab lished in accordance with the European conventions. It has been determined that the list of medicines for ART includes 14 trade names. The marketing analysis has shown that among 45 trade names registered there are single-source ones, such drugs as Puregon®, Pergoveris®, Ovitrel®, Klostilbegit®, Orlutran®, Tsetrotid®; therefore, the pharmaceutical development of these drugs is promising. Among the study list of INNs in the State Formulary of medicines of Ukraine there are no medicines, such as Choriogonadotropin alfa (Ovitrelle®), Corifollitropin alfa (Elonva®), fixed combination of Follitropin alfa / Lutropin alpha (Pergoveris 150/75®) with evidence based effectiveness; therefore, it is advisable to expand the list of hormonal drugs in the State Formulary of Ukraine. At the expense of budget funds in Ukraine it is financed in the range of 2.4-32.6 % of the need for reproductive health programs. It is necessary to increase funding to provide the need in hormonal drugs for ART. Conclusions. The results of marketing research can be used for reviewing the State Formulary of Ukraine, for practical measures on the effective implementation of public procurement to increase the availability of ART in Ukraine.